Table 3.
Summary of nintedanib-related toxicities
| |
CTC grade, n (%) |
||||
|---|---|---|---|---|---|
| Patients with drug-related AEs, n (%) | 1 | 2 | 3 | 4 | Total |
| Total |
18 (60) |
6 (20) |
2 (7) |
1 (3) |
27 (90) |
| Gastrointestinal disorders |
16 (53) |
7 (23) |
0 |
0 |
23 (77) |
| Nausea |
16 (53) |
4 (13) |
0 |
0 |
20 (67) |
| Vomiting |
14 (47) |
2 (7) |
0 |
0 |
16 (53) |
| Diarrhoea |
7 (23) |
5 (17) |
0 |
0 |
12 (40) |
| Investigations |
2 (7) |
1 (3) |
2 (7) |
1 (3) |
6 (20) |
| Hepatic enzyme increased |
0 |
1 (3) |
0 |
1 (3) |
2 (7) |
| ALT increased |
0 |
1 (3) |
0 |
0 |
1 (3) |
| AST increased |
0 |
1 (3) |
1 (3) |
0 |
2 (7) |
| GGT increased |
0 |
1 (3) |
0 |
0 |
1 (3) |
| CD4 decreased |
0 |
0 |
2 (7) |
0 |
2 (7) |
| General disorders |
5 (17) |
0 |
0 |
0 |
5 (17) |
| Fatigue | 5 (17) | 0 | 0 | 0 | 5 (17) |
Abbreviations: AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CTC Common Toxicity Criteria, GGT gamma-glutamyl transpeptidase.